Ecallantide: Difference between revisions
(Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)) |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 57: | Line 57: | ||
|?Has Route=Route | |?Has Route=Route | ||
|?Has Population=Population | |?Has Population=Population | ||
|format= | |format=table | ||
|headers=plain | |headers=plain | ||
| | |mainlabel=- | ||
|sort=Has Indication | |sort=Has Indication | ||
|limit=50 | |limit=50 | ||
Latest revision as of 21:56, 20 March 2026
General
- Type: Kallikrein inhibitor for angioedema
- Dosage Forms: 30mg
- Routes of Administration: SQ
- Common Trade Names: Kalbitor
Adult Dosing
Acute hereditary angioedema
- 30mg SQ
- Max 60mg/ 24 hr
Pediatric Dosing
Acute hereditary angioedema (>12yo)
- 30mg SQ
Special Populations
- Pregnancy Rating:C
- Lactation risk:Safety Unknown
- Renal Dosing
- Hepatic Dosing
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- anaphylaxis
- hypersensitivity reaction
Common
- headache
- nausea
- fatigue
- diarrhea
- URI
- injection site reaction
- nasopharyngitis
- vomiting
- pruritus
- abdominal pain
- fever
- anaphylaxis
Pharmacology
- Half-life: 2h
- Metabolism: CYP450
- Excretion: Urine
- Mechanism of Action: selectively, reversibly inhibits plasma kallikrein, preventing bradykinin generation
Comments
- Plasma kallikrein works as cofactor to formation of bradykinin which is implicated in angioedema
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Angioedema | 10 mg SC x3 at different sites (30 mg total) | Kallikrein inhibitor (HAE) | SC | Adult |